Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Kappa-opioid ligands in the study and treatment of mood disorders.

Carlezon WA Jr, Béguin C, Knoll AT, Cohen BM.

Pharmacol Ther. 2009 Sep;123(3):334-43. doi: 10.1016/j.pharmthera.2009.05.008. Epub 2009 Jun 2. Review.

2.

Modulation of serotonin transporter function by kappa-opioid receptor ligands.

Sundaramurthy S, Annamalai B, Samuvel DJ, Shippenberg TS, Jayanthi LD, Ramamoorthy S.

Neuropharmacology. 2017 Feb;113(Pt A):281-292. doi: 10.1016/j.neuropharm.2016.10.011. Epub 2016 Oct 12.

PMID:
27743931
3.
4.

Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.

Zhou L, Stahl EL, Lovell KM, Frankowski KJ, Prisinzano TE, Aubé J, Bohn LM.

Neuropharmacology. 2015 Dec;99:131-41. doi: 10.1016/j.neuropharm.2015.07.001. Epub 2015 Jul 6.

5.

The effects of kappa-opioid receptor ligands on prepulse inhibition and CRF-induced prepulse inhibition deficits in the rat.

Tejeda HA, Chefer VI, Zapata A, Shippenberg TS.

Psychopharmacology (Berl). 2010 Jun;210(2):231-40. doi: 10.1007/s00213-010-1799-6. Epub 2010 Mar 16.

6.

Kinase cascades and ligand-directed signaling at the kappa opioid receptor.

Bruchas MR, Chavkin C.

Psychopharmacology (Berl). 2010 Jun;210(2):137-47. doi: 10.1007/s00213-010-1806-y. Epub 2010 Apr 17. Review.

7.

Locus coeruleus kappa-opioid receptors modulate reinstatement of cocaine place preference through a noradrenergic mechanism.

Al-Hasani R, McCall JG, Foshage AM, Bruchas MR.

Neuropsychopharmacology. 2013 Nov;38(12):2484-97. doi: 10.1038/npp.2013.151. Epub 2013 Jun 21.

8.

N-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid receptor agonist with oral efficacy.

Béguin C, Potter DN, Dinieri JA, Munro TA, Richards MR, Paine TA, Berry L, Zhao Z, Roth BL, Xu W, Liu-Chen LY, Carlezon WA Jr, Cohen BM.

J Pharmacol Exp Ther. 2008 Jan;324(1):188-95. Epub 2007 Oct 19.

9.

The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward.

Tomasiewicz HC, Todtenkopf MS, Chartoff EH, Cohen BM, Carlezon WA Jr.

Biol Psychiatry. 2008 Dec 1;64(11):982-8. doi: 10.1016/j.biopsych.2008.05.029. Epub 2008 Jul 17.

10.

Role of kappa-opioid receptors in stress and anxiety-related behavior.

Van't Veer A, Carlezon WA Jr.

Psychopharmacology (Berl). 2013 Oct;229(3):435-52. doi: 10.1007/s00213-013-3195-5. Epub 2013 Jul 9. Review.

11.

Development of functionally selective, small molecule agonists at kappa opioid receptors.

Zhou L, Lovell KM, Frankowski KJ, Slauson SR, Phillips AM, Streicher JM, Stahl E, Schmid CL, Hodder P, Madoux F, Cameron MD, Prisinzano TE, Aubé J, Bohn LM.

J Biol Chem. 2013 Dec 20;288(51):36703-16. doi: 10.1074/jbc.M113.504381. Epub 2013 Nov 1.

12.

Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor.

Zheng Z, Huang XP, Mangano TJ, Zou R, Chen X, Zaidi SA, Roth BL, Stevens RC, Katritch V.

J Med Chem. 2017 Apr 13;60(7):3070-3081. doi: 10.1021/acs.jmedchem.7b00109. Epub 2017 Apr 3.

13.

Peptide kappa opioid receptor ligands: potential for drug development.

Aldrich JV, McLaughlin JP.

AAPS J. 2009 Jun;11(2):312-22. doi: 10.1208/s12248-009-9105-4. Epub 2009 May 9. Review.

14.

Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticity.

Van't Veer A, Bechtholt AJ, Onvani S, Potter D, Wang Y, Liu-Chen LY, Schütz G, Chartoff EH, Rudolph U, Cohen BM, Carlezon WA Jr.

Neuropsychopharmacology. 2013 Jul;38(8):1585-97. doi: 10.1038/npp.2013.58. Epub 2013 Feb 27.

15.

Opioid receptors: distinct roles in mood disorders.

Lutz PE, Kieffer BL.

Trends Neurosci. 2013 Mar;36(3):195-206. doi: 10.1016/j.tins.2012.11.002. Epub 2012 Dec 6. Review.

16.

Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism.

Kivell B, Uzelac Z, Sundaramurthy S, Rajamanickam J, Ewald A, Chefer V, Jaligam V, Bolan E, Simonson B, Annamalai B, Mannangatti P, Prisinzano TE, Gomes I, Devi LA, Jayanthi LD, Sitte HH, Ramamoorthy S, Shippenberg TS.

Neuropharmacology. 2014 Nov;86:228-40. doi: 10.1016/j.neuropharm.2014.07.016. Epub 2014 Aug 10.

17.

Development of κ opioid receptor antagonists.

Carroll FI, Carlezon WA Jr.

J Med Chem. 2013 Mar 28;56(6):2178-95. doi: 10.1021/jm301783x. Epub 2013 Feb 14. Review.

18.

Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.

Grimwood S, Lu Y, Schmidt AW, Vanase-Frawley MA, Sawant-Basak A, Miller E, McLean S, Freeman J, Wong S, McLaughlin JP, Verhoest PR.

J Pharmacol Exp Ther. 2011 Nov;339(2):555-66. doi: 10.1124/jpet.111.185108. Epub 2011 Aug 5.

19.

Activation of κ opioid receptors increases intrinsic excitability of dentate gyrus granule cells.

McDermott CM, Schrader LA.

J Physiol. 2011 Jul 15;589(Pt 14):3517-32. doi: 10.1113/jphysiol.2011.211623. Epub 2011 May 23.

20.

Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons.

Margolis EB, Hjelmstad GO, Bonci A, Fields HL.

J Neurosci. 2003 Nov 5;23(31):9981-6.

Supplemental Content

Support Center